Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Cardiomyopathy - cataract - hip spine disease describes the extremely rare triad of dilated cardiomyopathy, premature cataract, and articular disease of the hips and spine characterized by hip joint degeneration, irregular intervertebral disks, and platyspondyly. The ocular abnormalities are often the first symptoms to arise. There have been no further descriptions in the literature since 1985.
Biomarker and diagnostic research for cardiomyopathy-cataract-hip spine disease syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for cardiomyopathy-cataract-hip spine disease syndrome.
299 publications have been identified in PubMed for cardiomyopathy-cataract-hip spine disease syndrome. Kisho has analyzed 51 by research type. Research spans Review / Meta-Analysis (80%), Basic Science / Preclinical (10%), and Diagnostic / Biomarker (4%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 41 | 80% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 10:23 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research |
5 |
10% |
Testing and diagnosis research | 2 | 4% |
Patient case studies | 2 | 4% |
Disease patterns and progression | 1 | 2% |
Arulnathan E (2026). [PMID: 41971108](https://pubmed.ncbi.nlm.nih.gov/41971108/). *J Korean Soc Radiol*. [Review / Meta-Analysis]
Teoli D (2026). [PMID: 29630289](https://pubmed.ncbi.nlm.nih.gov/29630289/). *Unknown Journal*. [Diagnostic / Biomarker]
Fann Marko R (2025). [PMID: 39987477](https://pubmed.ncbi.nlm.nih.gov/39987477/). *Harefuah*. [Review / Meta-Analysis]
Zaki U (2025). [PMID: 39462499](https://pubmed.ncbi.nlm.nih.gov/39462499/). *Neonatology*. [Review / Meta-Analysis]
Pena C (2025). [PMID: 40146047](https://pubmed.ncbi.nlm.nih.gov/40146047/). *Minerva Med*. [Review / Meta-Analysis]
Jachiet V (2025). [PMID: 40476413](https://pubmed.ncbi.nlm.nih.gov/40476413/). *Rev Prat*. [Review / Meta-Analysis]
Ma R (2025). [PMID: 40992234](https://pubmed.ncbi.nlm.nih.gov/40992234/). *J Clin Anesth*. [Review / Meta-Analysis]
Paller AS (2025). [PMID: 40184496](https://pubmed.ncbi.nlm.nih.gov/40184496/). *Br J Dermatol*. [Review / Meta-Analysis]
Sánchez-Camacho A (2025). [PMID: 40406130](https://pubmed.ncbi.nlm.nih.gov/40406130/). *Front Immunol*. [Review / Meta-Analysis]
Zoref-Lorenz A (2025). [PMID: 39656557](https://pubmed.ncbi.nlm.nih.gov/39656557/). *Leuk Lymphoma*. [Review / Meta-Analysis]